Phenominer Database Results (19 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Average Type Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800 mammary gland integrity trait female 143.0 days-259.0 days 22 8.8 null 1.4 6.57 manual palpation method 0.0 crystalline implant 11382 81
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 99 and 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160.0 days-260.0 days 21 serial mean 145.0 d manual palpation method mammary gland 0.0 66104 76
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 99 and 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160.0 days-260.0 days 21 median 143.0 d manual palpation method mammary gland 0.0 66111 76
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female 259.0 days 21 7.0 null 1.16 5.3 necropsy 11368 75
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (for 196 days) Kurz SG, et al., Endocrinology. 2008 Apr 17 mammary gland integrity trait female  days-259.0 days 21 145.0 d manual palpation method 0 median 11375 75
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 147 and 195 days) Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30 mammary gland integrity trait female 206.0 days-264.0 days 31 141.0 d 4.85 27.0 manual palpation method mean 11748 144
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800 mammary gland integrity trait female 143.0 days-259.0 days 22 median 133.0 d manual palpation method 0 crystalline implant 65763 81
ACI/SegHsd binary logarithm of pituitary gland wet weight surgical implantation then 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Shull JD, et al., Mamm Genome. 2007 Sep 18;. pituitary gland mass female 252.0 days-266.0 days 9 7.15 null 0.12 0.36 post excision weight measurement pituitary gland 0 logarithm of pituitary wet weight 65770 331
ACI/SegHsd percentage of study population developing pituitary tumors during a period of time 17 beta-estradiol (27.5 mg) (between 146 and 202 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 pituitary gland integrity trait female 207.0 days-265.0 days 21 100.0 % ex vivo visual assessment 0 65551 76
ACI/SegHsd percentage of study population developing mammary tumors during a period of time bilateral ovariectomy then 17 beta-estradiol (27.5 mg) (for 140 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 201.0 days-203.0 days 11 0.0 % manual palpation method mammary gland 0 11379 76
ACI/SegHsd percentage of study population developing mammary tumors during a period of time 17 beta-estradiol (27.5 mg) (between 147 and 195 days) Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30 mammary gland integrity trait female 206.0 days-264.0 days 31 100.0 % manual palpation method 0 mean 66112 144
ACI/SegHsd percentage of study population developing mammary tumors during a period of time 17 beta-estradiol (27.5 mg) (for 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160.0 days-260.0 days 21 100.0 % manual palpation method mammary gland 0 65549 76
ACI/SegHsd pituitary gland wet weight surgical implantation then 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Shull JD, et al., Mamm Genome. 2007 Sep 18;. pituitary gland mass female 252.0 days-266.0 days 9 0.15 g 0.01 0.04 post excision weight measurement pituitary gland 0 13093 331
ACI/SegHsd percentage of study population developing mammary tumors during a period of time 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800 mammary gland integrity trait female 143.0 days-259.0 days 22 94.0 % manual palpation method 0 crystalline implant 65764 81
ACI/SegHsd percentage of study population developing pituitary tumors during a period of time bilateral ovariectomy then 17 beta-estradiol (27.5 mg) (for 140 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 pituitary gland integrity trait female 201.0 days-203.0 days 11 100.0 % ex vivo visual assessment 0 65561 76
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (between 99 and 197 days) Shull JD, et al., Carcinogenesis. 1997 Aug;18(8):1595-601 mammary gland integrity trait female 160.0 days-260.0 days 20 5.6 null necropsy 0.0 tumor size reach 1-1.5 cm 11377 76
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 193 and 199 days) Schaffer BS, et al., Cancer Res. 2006 Aug 1;66(15):7793-800 mammary gland integrity trait female 143.0 days-259.0 days 22 136.0 d 6.0 28.14 manual palpation method 0.0 crystalline implant 11383 81
ACI/SegHsd post-insult time to mammary tumor formation 17 beta-estradiol (27.5 mg) (between 147 and 195 days) Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30 mammary gland integrity trait female 206.0 days-264.0 days 31 median 140.0 d manual palpation method median 11750 144
ACI/SegHsd mammary tumor number 17 beta-estradiol (27.5 mg) (between 144 and 195 days) Shull JD, et al., Endocrinology 2001 Dec;142(12):5124-30 mammary gland integrity trait female 203.0 days-264.0 days 34 3.9 null 0.6 3.5 manual palpation method 0 11752 144